Table 1. Comparison of Symptom Reduction
| Intervention | PANSS Positive Score Change | PANSS Negative Score Change |
| Placebo | -5.4 | -3.6 |
| Lurasidone 40 mg | -7.7 | -6.0 |
| Lurasidone 120 mg | -7.7 | -5.2 |
| Olanzapine | -9.3 | -6.2 |
Lurasidone, a novel antipsychotic agent submitted for review to the Food and Drug Administration, with high binding affinities for D2, 5-HT-7, 5-HT-2A, and 5-HT-1A receptors, and is being studied as an antipsychotic with reduced likelihood of causing weight gain, central nervous system depression, and orthostatic hypotension. The multi-center, phase 3 Program to Evaluate Antipsychotic Response to Lurasidone (PEARL 2) trial was conducted to evaluate the efficacy of 2 doses of lurasidone in the treatment of individuals experiencing an acute exacerbation of schizophrenia.
Lurasidone: A Novel, Weight-Neutral Antipsychotic Agent
Комментариев нет:
Отправить комментарий